• Skip to primary navigation
  • Skip to main content
  • Skip to footer
NICO CorporationSecondary logo

NICO Corporation

Dedicated to revolutionizing minimally invasive neurosurgery

  • Home
  • Patients
  • Professionals
    • Our Capabilities
    • Our Integrated System
    • Our Surgical Focus
    • Our Impact
    • Published Data
    • Investigator Initiated Study Program
      • IIS Program Overview
      • IIS Areas of Interest (AOIs)
    • Donation Request
    • Global Distribution
    • NICO Technologies for Animal Health
    • Neurosurgeon Education
  • Company
    • Our Mission
    • Our Leadership Team
    • News & Events
    • Careers
  • LinkedIn
  • Twitter
  • YouTube

NICO Continues to Innovate with Smallest Trans-Sulcal Brain Access Tool in the World

Home » NICO Continues to Innovate with Smallest Trans-Sulcal Brain Access Tool in the World

May 1, 2018 by admin

For Immediate Release

Contact: Sue Goin
sue.goin@sapphire-com
317.402.8690

11 mm diameter BrainPath® offers smaller footprint and less displacement of brain tissue

NEW ORLEANS, May 1, 2018 — NICO Corporation introduced today the 11 mm diameter BrainPath – the world’s smallest trans-sulcal access system for subcortical surgery – at the America Association of Neurological Surgeons (AANS) Annual Scientific Meeting running through May 2 in New Orleans. The new device is part of the company’s expanding neurosurgery product line that addresses primary and secondary brain tumors and intracerebral hemorrhages.

“The narrower 11 mm BrainPath system is ideal for hematoma evacuation, even in long trajectory targets,” said Lawrence Dickinson, MD, neurosurgeon at Pacific Brain & Spine Medical Group in Castro Valley, CA. “The smaller caliber allows me to cannulate to the abnormality more efficiently and with less brain distortion, which is better for the patient.”

Like the 13.5 mm diameter BrainPath, the 11 mm is a designed for non-disruptive access to brain abnormalities and brain biopsy. The smaller 11 mm diameter affords the option for an even smaller footprint and less displacement of brain tissue. Dickinson said the 11 mm will be an ideal tool for brain tumor biopsy, adding that the corridor enables significant tissue yield for post-procedural tissue analysis, and having more tissue may reduce sampling error.

“In contemporary neuro-oncology, biopsy material is assayed using not only traditional histopathology and immunohistochemistry, but also genomic and proteomic analysis,” said Rohan Ramakrishna, MD, neurosurgeon at Weill Cornell Medicine in New York. “Samples may also be used for patient-derived xenografts in support of precision medicine applications. These analyses require significant tissue sampling, which the 11 mm BrainPath enables to a greater extent than traditional needle biopsy.”

More than 7,000 BrainPath procedures and 16,300 procedures using the NICO Myriad® resection tool have been successfully completed at over 210 BrainPath Centers in the U.S., Canada, the United Kingdom, Singapore, and Australia. BrainPath and Myriad work together as a system using imaging, navigation and intervention to achieve a true minimally invasive, trans-sulcal approach to neurosurgery. More than 50 peer-reviewed independent papers, posters and abstracts have been published on the technologies and improved clinical outcomes.

To learn more about the BrainPath Approach, visit NICOneuro.com, follow news updates on LinkedIn, and view surgical videos and patient stories on YouTube at NICOneuroCorp.

Uncategorized

Footer

OUR MISSION is SIMPLE

We provide proven and patented technologies that integrate imaging and intervention for a safe, minimally disruptive approach to brain surgery. This integration drives efficiencies for the patient, surgeon and healthcare provider.

Customer Service

 Tel: (317) 660-7118
 Email Us

Follow NICO Here

  • LinkedIn
  • Twitter
  • YouTube
Social Media Links

Search Our Website

privacy policy   ·    terms of use   ·    patents    ·   labeling

Copyright © 2023 · Nico Corporation · NICO Myriad and BrainPath are “tools” not “treatments”. Physicians should use their best judgment and clinical experience when deciding how to use the Myriad and BrainPath. The latest information, including contraindications, warnings and precautions can be obtained by consulting product labeling or your local NICO representative.